655 related articles for article (PubMed ID: 31443516)
1. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
Nedeljković M; Damjanović A
Cells; 2019 Aug; 8(9):. PubMed ID: 31443516
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586
[TBL] [Abstract][Full Text] [Related]
4. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Qayoom H; Wani NA; Alshehri B; Mir MA
Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
[TBL] [Abstract][Full Text] [Related]
5. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
6. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
[TBL] [Abstract][Full Text] [Related]
7. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
8. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
Guestini F; McNamara KM; Ishida T; Sasano H
Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
[TBL] [Abstract][Full Text] [Related]
11. Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer.
Kumari M; Krishnamurthy PT; Sola P
Curr Cancer Drug Targets; 2020; 20(8):559-572. PubMed ID: 32370716
[TBL] [Abstract][Full Text] [Related]
12. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.
Saatci O; Kaymak A; Raza U; Ersan PG; Akbulut O; Banister CE; Sikirzhytski V; Tokat UM; Aykut G; Ansari SA; Dogan HT; Dogan M; Jandaghi P; Isik A; Gundogdu F; Kosemehmetoglu K; Dizdar O; Aksoy S; Akyol A; Uner A; Buckhaults PJ; Riazalhosseini Y; Sahin O
Nat Commun; 2020 May; 11(1):2416. PubMed ID: 32415208
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer.
Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H
J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543
[TBL] [Abstract][Full Text] [Related]
14. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
[TBL] [Abstract][Full Text] [Related]
15. Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance.
Xia M; Zu X; Chen Z; Wen G; Zhong J
Cancer Lett; 2021 Dec; 523():100-110. PubMed ID: 34601022
[TBL] [Abstract][Full Text] [Related]
16. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
[TBL] [Abstract][Full Text] [Related]
17. Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer.
Azari M; Bahreini F; Uversky VN; Rezaei N
Biochem Pharmacol; 2023 Apr; 210():115459. PubMed ID: 36813121
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
Chen DR; Lu DY; Lin HY; Yeh WL
Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
20. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.
So JY; Ohm J; Lipkowitz S; Yang L
Pharmacol Ther; 2022 Sep; 237():108253. PubMed ID: 35872332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
